WO2005080564A1 - 抗ヒトpca-1抗体 - Google Patents
抗ヒトpca-1抗体 Download PDFInfo
- Publication number
- WO2005080564A1 WO2005080564A1 PCT/JP2004/012461 JP2004012461W WO2005080564A1 WO 2005080564 A1 WO2005080564 A1 WO 2005080564A1 JP 2004012461 W JP2004012461 W JP 2004012461W WO 2005080564 A1 WO2005080564 A1 WO 2005080564A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- human
- pca
- prostate cancer
- sample
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
Definitions
- the present invention relates to an antibody that immunospecifically recognizes a human PCA-1 polypeptide. More specifically, the present invention relates to an antibody that immunospecifically recognizes the amino acid sequence of SEQ ID NO: 4 or a partial sequence thereof.
- Prostate cancer is a malignant tumor that ranks highest in male cancer morbidity and mortality in Europe and the United States. In Japan, the morbidity and mortality of prostate cancer have been increasing rapidly in recent years with the Western diet and the elderly in the diet.
- prostate cancer relies on histopathological judgments such as tumor grade and stage, and biologic parameters such as PSA values.
- PSA prostatic specific antigen
- the measurement of prostatic specific antigen (PSA) concentration in blood has rapidly spread in mass screenings and health check-ups, and prostate cancer can be detected relatively early.
- PSA levels are seen after the onset of prostate cancer, and blood PSA levels are diagnosed as benign prostatic hyperplasia (BPH) and prostatitis.
- BPH benign prostatic hyperplasia
- PCA-1 also called human AlkB homolog 3 (hABH3)
- hABH3 human AlkB homolog 3
- an object of the present invention is to provide an antibody that recognizes human PCA-1 polypeptide with high sensitivity and high specificity.
- the present inventors have conducted intensive studies to achieve the above object. As a result, the use of a polypeptide containing an amino acid sequence of a specific portion of human PCA-1 polypeptide makes it possible to obtain human PCA-11 polypeptide with high sensitivity and high sensitivity. They found that an antibody recognizing with high specificity could be obtained, and completed the present invention.
- the present invention relates to the following (1) to (11).
- a method for diagnosing prostate cancer comprising the following steps:
- a method for distinguishing between prostate cancer and benign prostatic hyperplasia comprising the following steps: a) human PCA-1 in a sample derived from a human who is at risk of developing prostate cancer or benign prostatic hyperplasia; Detecting and quantifying using the antibody according to any one of (1) to (3) above; b) If human PCA-1 is detected in the sample, it is determined that the human is at risk of developing prostate cancer, and if human PCA-1 is not detected in the flexible fiber Determine that the human is at risk for developing normal or benign prostatic hyperplasia;
- a kit for detecting and quantifying human PCA-1 comprising the antibody according to any one of (1) to (3) above.
- a kit for diagnosing prostate cancer comprising the antibody according to any one of (1) to (3).
- a kit for distinguishing between prostate cancer and benign prostatic hyperplasia comprising the antibody according to any one of (1) to (3).
- a polypeptide comprising the amino acid sequence of SEQ ID NO: 4 or a partial sequence thereof.
- FIG. 1 shows Western blot analysis of the expression of PCA-1 in a prostate cancer cell line. Overexpression of about 4 OkDa protein in PC-3 and DU145 cell lines.
- FIG. 2 is a diagram showing the results of immunohistochemical detection of PCA-1 in the prostate.
- A Heterogeneous expression in prostate adenocarcinoma. Not found in adjacent normal glands (X100).
- B Negative staining (X100).
- FIG. 3 is a diagram showing immunohistochemical staining of PCA-1 in the prostate.
- PC A-1 is expressed in prostate cancer but not in the adjacent normal prostate.
- B shows cases of prostate cancer in which PC A-1 is localized in the nucleus.
- PCA-1 is a molecule also called human AlkB homolog 3 (hABH3) or DEPC-1.
- the nucleotide sequence of the cDNA of the normal human PCA-1 gene is SEQ ID NO: 1, in which the residues at positions 407-127 (SEQ ID NO: 3) correspond to the protein coding region, Encodes a human PCA-1 polypeptide consisting of the amino acid sequence of SEQ ID NO: 2.
- the human PCA-1 gene is encoded by the locus at 11p11 on chromosome 1 and the nucleotide sequence of the chromosome DNA around the PCA-1 gene is gene punk accession number NT-009237. (NC BI homepage).
- the antibody of the present invention immunospecifically recognizes the amino acid sequence of SEQ ID NO: 4 (RRAPEPRVIDREG), which is a part of the human PCA-1 polypeptide (amino acids 64 to 76), or a partial distribution sequence thereof. It is characterized by the following.
- the length of the amino acid sequence recognized by the antibody of the present invention is not particularly limited as long as it has immunogenicity as an epitope, but is preferably 6 amino acids or more, more preferably 8 amino acids or more, and still more preferably 1 amino acid or more. 0 amino acid or more, most preferably the full length of the amino acid sequence of SEQ ID NO: 4.
- Immunospecific recognition means that the antibody exhibits a substantially higher affinity for a particular sequence than its affinity for other sequences.
- the term “antibody” includes polyclonal antibodies, natural antibodies such as monoclonal antibodies (mAb), chimeric antibodies that can be produced using gene recombination techniques, humanized antibodies, single-chain antibodies, and transgenes that produce human antibodies. Examples include, but are not limited to, human antibodies that can be produced using nick animals and the like, antibody fragments produced by Fab expression libraries, and binding fragments thereof. Preferably, the antibodies are polyclonal antibodies, monoclonal antibodies and binding fragments thereof.
- the binding fragment means a partial region of the aforementioned antibody, and specifically, for example, F (ab ') 2 , Fab, Fab, Fv (variable fragment of antibody), sFv, dsFv (disu ⁇ phide s tabilised) Fv), dAb (single domain antibody) and the like (Exp. Opin. Ther. Patents, Vol. 6, No. 5, p. 441-456, 1996).
- the class of the antibody is not particularly limited, and includes antibodies having any isotype such as IgG, IgM, IgA, IgD or IgE. Preferably, it is IgG or IgM, and more preferably IgG in consideration of easiness of purification and the like.
- the polyclonal antibody or the monoclonal antibody can be produced by an existing general production method. That is, for example, an immunogen may be added to a mammal, for example, in the case of a polyclonal antibody, in the case of a mouse, rat, hamster, guinea pig, egret, cat, dog, puta together with Freund's adjuvant, if necessary. Immunize a mouse, rat, hamster, hamster, guinea pig, goat, goat, or rabbit, and in the case of a monoclonal antibody, a mouse, rat, hamster.
- the immunogen is used, if necessary, by crosslinking it with a carrier.
- a carrier examples include BSA, KLH and the like.
- a protein derived from an animal to be immunized for example, serum protein or the like may be used as a carrier.
- a polypeptide having the amino acid sequence of SEQ ID NO: 4 or a partial sequence thereof is used.
- the polypeptide is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4 or a partial sequence thereof.
- the length of the partial sequence is not particularly limited as long as it has immunogenicity as an epitope, but is preferably 6 amino acids or more, more preferably 8 amino acids or more, and still more preferably 10 amino acids or more. More preferably, a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4 is used.
- One or more amino acids may be added for the purpose of crosslinking the polypeptide to a carrier or the like.
- the number of amino acids added is not particularly limited, but is preferably 1 to 10, more preferably 1 to 5, still more preferably 1 to 2, and most preferably 1 to 10, in consideration of the specificity of the antibody to be produced. Preferably one.
- the amino acid to be added may be at the N-terminus or the C-terminus of the polypeptide, but is preferably at the N-terminus.
- the type of amino acid to be added may be any of the 20 types of amino acids known per se, but preferably the added amino acid contains at least one cysteine. More preferably, the amino acid added consists of cysteine.
- the polyclonal antibody can be specifically produced as follows. That is, the immunogen is used in mice, rats, hamsters, guinea pigs, goats, magpies or ephedras, preferably in goats, emas or ephedras, and more preferably in subcutaneous, intramuscular, intravenous, or hoodpads of egrets. Immunization is given by injecting one or several times intraperitoneally. Usually, immunization is performed 1 to 5 times about every 1 to 14 days after the first immunization, and serum is obtained from the immunized mammal about 1 to 5 days after the last immunization.
- serum As a polyclonal antibody, but it is preferable to use saturated ammonium sulfate, u-glupurine precipitation, force proic acid, force prillic acid, ion exchange chromatography (DEAE or DE52, etc.). It is isolated and Z or purified by affinity column chromatography using an anti-immunoglobulin column or a protein A / G column, a column cross-linked with an immunogen, or the like.
- Monoclonal antibodies were prepared from hybridomas (S4 combined cells) from the antibody-producing cells obtained from the above-mentioned immunized animal and myeloma cells (myeloma cells) without autoantibody-producing ability, and the hybridomas were cloned. It is produced by selecting a clone that produces a monoclonal antibody showing specific affinity for the immunogen used for immunizing the mammal.
- a monoclonal antibody can be specifically produced as follows. That is, the immunogen is administered subcutaneously, intramuscularly, or intravenously in mice, rats, or hamsters (including transgenic animals created to produce antibodies from other animals, such as human antibody-producing transgenic mice). Immunization is carried out by injecting one or several times or implanting into the inside, foot pad II or intraperitoneal cavity. Usually, immunization is performed 1 to 4 times about every 1 to 14 days after the initial immunization, and antibody producing cells are obtained from the immunized mammal about 1 to 50 after the final immunization.
- hybridomas fused cells
- the modification can be performed according to the following modification method. That is, antibody producing cells contained in the spleen, lymph node, bone marrow, tonsil, etc., preferably in the spleen, obtained from the mammal immunized as described above, and preferably in mice, rats, guinea pigs, hamsters, and egrets.
- a mammal such as a human, more preferably a mouse, rat or a human derived mouse cell line which has no autoantibody-producing ability.
- myeloma cells used for cell fusion include mouse-derived myeloma P3 / X63-AG8.63 (653; ATCC No. CRL1580), P3 / NSI / tri-Ag4-1 (NS-1), and P3 / X63-Ag8 Ul (P3U1), SP2 / 0-Agl4 (S P 2/0, Sp2), PAI, F0 or Kaya 147, Rat-derived Mie Mouth 210RCY3—Ag. 2. 3., Human-derived Mie Mouth Ma U-266AR1, GM1500-6TG-A1-2, UC729-6, CEM-AGR, D1R11 or CEM-T15 can be used.
- Screening of a hybridoma clone producing a monoclonal antibody is performed by culturing a hybridoma, for example, in a microtiter plate, and reacting the culture supernatant of a well in which proliferation has been observed with the immunogen used in the above immunization.
- the sex can be determined by, for example, measuring an enzyme immunoassay such as RIA or ELISA.
- Production of the monoclonal antibody from the hybridoma was performed by in vitro culturing the hybridoma in an in vivo mouth or in ascites of a mouse, a rat, a guinea pig, a hamster or a heron, preferably a mouse or a rat, more preferably a mouse ascites. It can be carried out by isolating from a culture supernatant or ascites of a mammal.
- the hybridoma When culturing in vitro, the hybridoma is grown, maintained, and maintained in accordance with various conditions such as the characteristics of the cell type to be cultured, the purpose of the test and research, and the culture method, and the monoclonal antibody is added to the culture supernatant. It can be carried out using a known nutrient medium as used for production or any nutrient medium derived and prepared from a known basal medium.
- the monoclonal antibody be isolated and Z- or purified similarly to the polyclonal-nanore antibody described above.
- the chimeric antibody is described in, for example, “Experimental Medicine (Temporary Extra Number), Vol. 1.6, No. 10, 1988J, Japanese Patent Publication No. 3-73280, and the like. No. 506458, Japanese Patent Application Laid-Open No. 62-296890 and the like, human antibodies are described in, for example, ⁇ Nature Genetics, Vol. 15, p. 146-156, 1997 "," Nature Genetics, Vol. 7, p. 13—21, 1994 ", Japanese Patent Application Publication No. 4-504365, International Application Publication W094 / 25585,” Nikkei Science, 6 Monthly, pp. 40-50, 1990), Nature, Vol. 368, p. 856-859, 1994, Tokiohei No. 6-500233, etc. be able to.
- ⁇ Fab ′ can be produced by treating immunoglobulin with pepsin or papain, which are proteases, respectively.
- the antibody of the present invention can recognize human PCA-1 polypeptide with extremely high sensitivity and high specificity, it can be used for detection, quantification, concentration, and the like of human PCA-1.
- a sample to be measured is brought into contact with the antibody of the present invention, and the specific binding of the antibody to the sample is detected and quantified.
- a method known per se such as Western blotting, immunohistochemical staining, ELISA, RIA, surface plasmon resonance, and protein chip can be used.
- Samples that can be used for the detection and quantification of human PCA-1 are not particularly limited, and include, for example, tissues separated from humans (eg, prostate, thymus, testis, etc.) and cells (cells separated from tissues). Cells (including cultured cells), normal cells, cancer cells, cell lines, etc., liquid components (blood, serum, plasma, semen, saliva, urine, sweat, etc.), and extracts thereof.
- a culture eg, culture supernatant or the like
- Conditions for the type of culture solution, culture time, and the like in the preparation of the culture are those commonly used in the field.
- Such samples include those that have been subjected to purification, fixation, heating, dissolution, concentration, etc.
- Human PCA-1 has high translocation to the nucleus and was not considered to be secreted out of the cell, but the antibody of the present invention provides human PCA-1 polypeptide with extremely high sensitivity and high specificity.
- the detection and quantification method of the present invention a very small amount of human PCA-1 polypeptide secreted extracellularly can be detected and quantified. Therefore, the method for detecting and quantifying human PCA-1 of the present invention Cultures that can be prepared by culturing liquid components (blood, serum, plasma, semen, saliva, urine, sweat, etc.) or tissues or cells isolated from humans in an appropriate culture medium (eg, Suitable for detection and quantification of human PCA-1 polypeptide contained in culture supernatants.
- a sample is dissolved in an appropriate lysis buffer (1 sis buffer) or the like, and a protein component is extracted.
- the extracted sample is subjected to electrophoresis (eg, SDS-PAGE, isoelectric focusing, two-dimensional electrophoresis, etc.) and separated.
- electrophoresis eg, SDS-PAGE, isoelectric focusing, two-dimensional electrophoresis, etc.
- Transfer the proteins in the gel to a membrane (eg, nitrocellulose membrane, PVDF membrane, etc.).
- the membrane is treated with BSA or the like to suppress non-specific binding, and then the protein transferred on the membrane is contacted with the antibody of the present invention.
- the membrane is washed with an appropriate washing buffer, and the specific binding of the antibody of the present invention is detected by a method known per se (for example, a method using a labeled secondary antibody).
- a method known per se for example, a method using a labeled secondary antibody.
- a section is prepared using a frozen or paraffin-embedded sample, and the section is fixed on a slide glass or the like. If necessary, the section may be subjected to a treatment such as a deparaffinization treatment or a heating treatment. Subsequently, the section is stained with the antibody of the present invention. The sections are washed with an appropriate washing buffer, and the specific binding of the antibody of the present invention is detected by a method known per se (for example, a method using a labeled secondary antibody). As a result, human PCA- Detect and quantify 1.
- Examples of the ELISA method include a sandwich ELISA method using two kinds of antibodies of the present invention or a combination of the antibody of the present invention and another antibody that immunospecifically recognizes human PCA-1 polypeptide. I can do it.
- the detection and quantification method of the present invention can be used for diagnosis of a disease in which human PCA-1 is involved in the onset and progression of the disease, and a disease in which human PCA-1 can be used as a marker.
- the disease includes, for example, cancer (prostate pain, breast cancer, Teng cancer, etc.).
- cancer prostate pain, breast cancer, Teng cancer, etc.
- the detection and quantification method of the present invention is useful for diagnosis of prostate cancer.
- PCA-1 expression is not enhanced in benign prostatic hyperplasia, so the detection and quantification method of the present invention is particularly useful for discriminating between prostate cancer and benign prostatic hyperplasia. It is. That is, the present invention is a method for diagnosing prostate cancer, comprising the following steps: a) detecting and quantifying human PCA-1 in a human-derived sample using the antibody of the present invention;
- prostate cancer is a concept that broadly encompasses cancers that have occurred in the prostate. Not only adenocarcinoma that has occurred in the prostate but also squamous cell carcinoma, transitional cell carcinoma, neuroendocrine cancer, undifferentiated cancer And the like.
- the prostate cancer is an adenocarcinoma arising in the prostate.
- any of the above-mentioned samples can be used, but preferably the prostate, cells isolated from the prostate, prostate cancer cells, prostate cell lines, serum and Extract. Further, a prostate, a cell isolated from the prostate, a prostate cancer cell, and a culture that can be prepared by culturing a prostate cell line in an appropriate culture medium are also preferable as the sample.
- human PCA-1 when human PCA-1 is detected in a human-derived sample, the human is at risk (or high) or at risk of developing prostate cancer ( Or high). Conversely, if no human PCA-1 is detected in the human sample, it is determined that the human is not at risk (or low) of developing prostate cancer or is not (or low) at risk of developing prostate cancer.
- prostate cancer when human PCA-1 was detected in a human-derived sample, prostate cancer was developed when the amount of human PCA-1 in the sample was large as compared to when the amount was small. It can be determined that the risk or risk of developing is higher.
- a sample derived from a human developing prostate cancer positive control
- a sample derived from a healthy human negative control
- the accuracy of diagnosis can be improved.
- Other diagnostic methods for prostate cancer The palpation inspection method using the prostate specific antigen (PSA) concentration of serum and secondary, before the pathological examination with prostate needle biopsy samples (pathological T stage (pathological T st age: P T )), Grayson cancer Scores (Gleason tumor score), ultrasonography, MRI, CT, bone scintigraphy, etc.
- PSA prostate specific antigen
- the present invention also provides a method for distinguishing between prostate cancer and benign prostatic hyperplasia, comprising the steps of:
- the “human at risk of developing prostate cancer or prostatic hypertrophy” can include all male humans, but is preferably a subjective symptom (eg, feeling of residual urine), a palpation examination (eg, lump of the prostate). Men who are suspected to have developed prostate cancer or prostatic hyperplasia due to serum PSA concentration test (high PSA concentration etc.).
- the sample used in the determination method of the present invention is the same as the sample used in the above-described diagnostic method.
- ⁇ A in which human: PCA-1 was detected in a human sample was judged to be at risk of developing prostate cancer, and human PCA-1 was detected in the sample. If no is detected, it is determined that the human is at risk for developing normal or benign prostatic hyperplasia.
- the present invention also relates to a kit for detecting and quantifying human PCA-1, which comprises the antibody of the present invention.
- human PCA-1 can be detected and quantified by the method described above.
- the kit can further include a labeled secondary antibody, a substrate, and the like.
- the present invention also relates to a kit for diagnosing prostate cancer, comprising the antibody of the present invention. Using the kit, prostate cancer can be diagnosed by the method described above.
- the kit preferably further includes a note stating that the antibody of the present invention can or should be used for diagnosis of prostate cancer.
- the kit can further include a labeled secondary antibody, a substrate, and the like.
- the present invention also relates to a kit for discriminating between prostate cancer and benign prostatic hyperplasia, comprising the antibody of the present invention.
- prostate cancer and benign prostatic hyperplasia can be distinguished by the method described above.
- the kit preferably further includes a description stating that the antibody of the present invention can or should be used for discriminating between prostate cancer and benign prostatic hyperplasia.
- the kit can further include a labeled secondary antibody, a substrate, and the like.
- Pre-immune sera were collected from two New Zealand white herons (Japan SLC, Inc.) before the first immunization.
- the immunogen the amino acid sequence of CRRAPEPRVIDREG (SEQ ID NO: 5), in which one cysteine residue is added to the N-terminal of the amino acid sequence of RRAPEPRVIDREG (SEQ ID NO: 4), which is a partial sequence of human PCA-1 polypeptide, was used.
- the polypeptide was cross-linked to KLH by the MBS method (Sigma dienosis).
- the peptide (about 0.5 mg) cross-linked to KLH was emulsified in an equal volume of Freund's adjuvant, and injected subcutaneously at a plurality of sites of a perch.
- Human prostate cancer cell lines PC-3 and DU-145 obtained from ATCC (American Type Culture Collection), 10% heat-inactivated fetal bovine serum (PAA Lab.) And 1 OmgZm 1 kanamycin in a suitable culture medium supplemented with (sigma), 3 7 ° C, and cultured under the 51 ⁇ 2C0 2 environment.
- Cells are placed in 1 ml ice-cold lysis buffer (1% NP4O, 150 mM NaC1, 50 mM Tris pH 7.4, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride and 1 mM benzamidine). Thawed on ice.
- lysates were centrifuged and analyzed by 10% SDS-PAGE to remove insolubles.
- the lysate protein was transferred from SDS-polyacrylamide gel to trocellulose membrane (Schleicher & Schuell Bio Science Neyring), and the intrinsic activity was 3% ⁇ serum albumin (BSA) TBS-T (20 mM Tris—HC 1 Block with pH 8.0, 137 mM NaC1, 0.1% Tween 20), and with 0.2 ⁇ g / m1 anti-PC A-1 polyclonal antibody (produced in Example 1) at room temperature Incubate for 1 hour and wash 3 times with TBS-T.
- BSA serum albumin
- the membrane was exposed to HRP (Horseradish peroxidase) bridge anti-peacock IgG (Santa Cruz Biotech.) Diluted in TBS-T. After washing three times with TBST-T, bound HRP The crosslinked product (conjugate) was visualized with an enhanced chemiluminescent reagent (Wako Pure Chemical ⁇ fc $ ⁇ ).
- HRP Haseradish peroxidase
- the detected band was a single band, and non-specific binding to proteins other than human PCA-1 polypeptide was not observed. (Example 3)
- the anti-PCA-1 polyclonal antibody produced according to Example 1 was used for immunohistochemical analysis of PCA-1 expression in 70 prostate cancer samples.
- Table 1 summarizes the correlation of PCA-1 expression in prostate cancer by immunohistological analysis. As can be seen from Table 1, the expression of PCA-1 was positive in 90% (63/70) of Toori Tateori in the cancerous part. All of the 70 non-cancerous prostate tissues were negative. These results suggest that PCA-1 is very specifically expressed in prostate cancer. (Example 4)
- the anti-PCA-1 polyclonal antibody produced according to Example 1 was used for immunohistochemical analysis of PCA-1 expression in 57 prostatic hyperplasia samples. Prostate cancer samples were used as positive controls. Immunohistochemical analysis was performed under the same conditions as in Example 3.
- PCA-1 prostatic hyperplasia
- prostate cancer a positive control, had positive expression of PCA-1 and normal gland ducts around the cancer had negative expression of PCA-1.
- the antibody of the present invention can recognize the human PCA-1 polypeptide, whose expression is enhanced in prostate cancer, with high sensitivity and high specificity, it can be used for the detection, quantification, and diagnosis of prostate cancer of human PCA-1. Can be used.
- the prostate cancer diagnosis method of the present invention is effective for prostate cancer diagnosis, follow-up, prediction of prognosis, and the like. Further, the antibody of the present invention is useful for discriminating between prostate cancer and benign prostatic hyperplasia, which has been difficult by conventional palpation examination or diagnosis based on blood PSA concentration.
- SEQ ID NO: 4 Partial sequence of human PCA-1 polypeptide
- SEQ ID NO: 5 immunogen for preparing anti-human PCA-1 antibody
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-047034 | 2004-02-23 | ||
JP2004047034 | 2004-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005080564A1 true WO2005080564A1 (ja) | 2005-09-01 |
Family
ID=34879462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/012461 WO2005080564A1 (ja) | 2004-02-23 | 2004-08-24 | 抗ヒトpca-1抗体 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005080564A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007015587A1 (ja) * | 2005-08-04 | 2007-02-08 | Osaka University | アポトーシス促進剤、細胞増殖阻害剤、癌の予防・治療剤、及びそのスクリーニング方法 |
-
2004
- 2004-08-24 WO PCT/JP2004/012461 patent/WO2005080564A1/ja active Application Filing
Non-Patent Citations (4)
Title |
---|
DATABASE NUCLEOTIDE [online] TSUJIKAWA K. ET AL: "Homo sapiens mRNA expressed in prostate cancer and thymus", XP002981762, accession no. NCBI Database accession no. AB042029 * |
DUNCAN T. ET AL: "Reversal of DNA alkylation damage by two human dioxygenases.", PROC.NATL.ACAD.SCI.USA., vol. 99, no. 26, 24 December 2002 (2002-12-24), pages 16660 - 16665, XP002277808 * |
KUROWSKI M.A. ET AL: "Phylogenomic identification of five new human homologs of the DNA repair enzyme AlkB.", BMC GENOMICS., vol. 4, no. 48, 2003, pages 1 - 6, XP002981763, Retrieved from the Internet <URL:URL:http://www.biomedcentral.com/1471-2164/4/48> [retrieved on 20040915] * |
TSUJIKAWA ET AL: "DNA, RNA Alkyl-ka Sonsho Shufuku Koso PCA-1(hABH3) no Hatsugen to Kino Kaiseki. (Abstract O41-2)", pages 525, XP002996278 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007015587A1 (ja) * | 2005-08-04 | 2007-02-08 | Osaka University | アポトーシス促進剤、細胞増殖阻害剤、癌の予防・治療剤、及びそのスクリーニング方法 |
JP5051454B2 (ja) * | 2005-08-04 | 2012-10-17 | 国立大学法人大阪大学 | アポトーシス促進剤、細胞増殖阻害剤、癌の予防・治療剤、及びそのスクリーニング方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2015238877B2 (en) | Cancer detection method | |
HUE033628T2 (en) | Method for detecting pancreatic cancer | |
EP2363471A1 (en) | Immunoassay method for human cxcl1 protein | |
CA2879304C (en) | Method for detecting cancer | |
JPWO2006098464A1 (ja) | 前立腺がんの診断方法 | |
JPH08511624A (ja) | 腫瘍の診断方法及び分析方法 | |
WO2014192974A1 (ja) | 抗lgr6抗体を含む癌の検出用又は診断用試薬 | |
KR101777259B1 (ko) | En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 | |
KR101777254B1 (ko) | En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 | |
TWI667479B (zh) | 乳癌生物標記 | |
KR20130108324A (ko) | 대장직장암 마커에 대한 항체 | |
CN113272332B (zh) | 抗Claudin18.2的抗体及其应用 | |
WO2005080564A1 (ja) | 抗ヒトpca-1抗体 | |
CA2674739C (en) | In vitro method for diagnosing prostate cancer | |
CN110049996B (zh) | En2蛋白的免疫原性片段肽或特异性识别其的抗体组合物 | |
CN110036119B (zh) | 卵巢癌生物标记及其应用 | |
TWI702400B (zh) | 偵側卵巢癌之方法、監控卵巢癌病患之卵巢癌發展之方法及可辨識切割型c3多胜肽之試劑的用途 | |
EP4166945A1 (en) | Novel biomarkers of membranous glomerulonephritis | |
CN110865184B (zh) | Srsp蛋白和srsp抗原表位肽的应用及诊断和治疗肿瘤的产品 | |
WO2022202826A1 (ja) | 悪性膵嚢胞性腫瘍の判定補助方法及び判定補助用キット | |
KR20080080583A (ko) | 혈관 노화의 예지 인자 및 그 이용 | |
US20100093005A1 (en) | Identifying duct cancers | |
JP2004024195A (ja) | ヒトsnk蛋白質に対するモノクローナル抗体及び甲状腺癌判別方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |